Prioritizing Your Long-Term Health
At a Glance
Narcolepsy Type 1 affects more than alertness: it is linked with weight gain, high blood pressure, blood sugar problems, mood symptoms, attention difficulties, and sleep apnea. Regular checks of weight, blood pressure, A1c, cholesterol, and mental health support safer long-term care.
Managing Narcolepsy Type 1 (NT1) is a long-term commitment that extends beyond staying awake. Because the loss of orexin in the brain affects systems that regulate metabolism, heart rate, and mood, people living with NT1 face a higher risk for certain health conditions over time [1][2]. Staying healthy involves individualized monitoring and a “whole-person” approach to care.
Metabolic and Heart Health
The loss of orexin in the brain may alter how your body regulates energy and weight. As a result, cardiometabolic issues are commonly seen alongside NT1, though factors like obesity, sleep apnea, and treatments also play a major role.
- Weight Management: Many people with NT1 struggle with obesity or sudden weight gain, often beginning early in the course of the disease [1][3].
- Diabetes and Blood Sugar: Rates of prediabetes and Type 2 diabetes are higher in the NT1 population compared to those without narcolepsy [1][2].
- Blood Pressure and Cholesterol: Hypertension (high blood pressure) and dyslipidemia (unhealthy cholesterol levels) are frequent [1]. Additionally, some people with NT1 experience “non-dipping” blood pressure, meaning their blood pressure does not safely drop at night, which can strain the heart [4].
How Medications Affect Your Risk
The medications used to treat NT1 can interact with your cardiovascular health in different ways. Work with your doctor to choose the safest options for your profile.
- Stimulants and Wake-Promoters: Drugs like methylphenidate, amphetamines, and solriamfetol can increase your heart rate and blood pressure [5][6]. Regular blood pressure monitoring is recommended while taking these [7].
- Oxybate and Sodium: Standard sodium oxybate contains a high amount of sodium, which may be a concern for those with existing heart issues [8]. Low-sodium oxybate offers a significant reduction in sodium and may be a better choice for maintaining healthy blood pressure, though it carries the same neurological risks [9].
- Weight Changes: Medication effects on weight vary widely. Some wake-promoting agents may suppress appetite, while other treatments might influence weight differently [10][11].
Mental Health and Cognition
NT1 also profoundly impacts your emotional well-being and how you process information.
- Depression and Anxiety: These are the most common psychiatric comorbidities in NT1 [12].
- Suicide Risk: Suicidal thoughts can occur and require immediate professional attention. If you experience thoughts of self-harm, please reach out to an emergency service or a national crisis line immediately. While effective narcolepsy treatment may improve overall mood and reduce these thoughts, it does not guarantee protection against depression or suicidality [12].
- ADHD and Attention: A significant number of people with NT1 also experience symptoms of ADHD, particularly the inattentive type [13]. You may find that even when you aren’t feeling sleepy, it is still difficult to maintain focus or organize tasks [14].
Your Long-Term Care Plan
Because NT1 impacts so many systems, your “care team” should ideally include more than just a sleep specialist.
- Individualized Screenings: Discuss a schedule with your doctor for checking your blood pressure, weight, blood sugar (A1c), and cholesterol. The frequency should be based on your age, BMI, family history, and the medications you take [7][15].
- Mental Health Check-ins: Screenings for depression and anxiety should be a routine part of your follow-up visits [12].
- Sleep Apnea Monitoring: Many people with NT1 also develop Obstructive Sleep Apnea (OSA), which can make narcolepsy symptoms worse if left untreated [16].
- Multidisciplinary Approach: Depending on your health, your team might include a primary care doctor, a cardiologist, and a therapist or psychiatrist to help manage the full range of NT1’s long-term effects [7][17].
Common questions in this guide
What long-term health problems are linked with Narcolepsy Type 1?
Can narcolepsy medications affect my heart or blood pressure?
How often should I check blood pressure, A1c, and cholesterol with NT1?
Does Narcolepsy Type 1 increase the risk of depression or anxiety?
Should people with NT1 be evaluated for sleep apnea?
Which doctors should be involved in long-term NT1 care?
Can a severity scale help track my narcolepsy treatment?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is my current cardiovascular risk score, and how do my narcolepsy medications impact that risk?
- 2.Since I may be at a higher risk for high blood pressure and prediabetes, how often should we be screening my blood pressure, A1c, and cholesterol?
- 3.Can we use a tool like the Narcolepsy Severity Scale to track my progress and see if my current treatment is effectively managing all my symptoms?
- 4.If I experience new symptoms of anxiety or low mood, who on my care team should I contact first, and how will we adjust my medications?
- 5.Would it be beneficial for me to see a primary care doctor or cardiologist to proactively manage the metabolic risks associated with my condition?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (17)
- 1
Narcolepsy and metabolic disease: A meta-analytic synthesis.
Zhang X, Yin W, Ren J, et al.
Sleep medicine reviews 2026; (87()):102264 doi:10.1016/j.smrv.2026.102264.
PMID: 41747645 - 2
Narcolepsy Is Associated With Subclinical Cardiovascular Disease as Early as Childhood: A Big Data Analysis.
Kaufmann CN, Riaz M, Park H, et al.
Journal of the American Heart Association 2025; (14(12)):e039899 doi:10.1161/JAHA.124.039899.
PMID: 40207482 - 3
The role of mtDNA haplogroups on metabolic features in narcolepsy type 1.
Caporali L, Moresco M, Pizza F, et al.
Mitochondrion 2022; (63()):37-42 doi:10.1016/j.mito.2022.01.005.
PMID: 35051655 - 4
Cardiovascular disorders in narcolepsy: Review of associations and determinants.
Jennum PJ, Plazzi G, Silvani A, et al.
Sleep medicine reviews 2021; (58()):101440 doi:10.1016/j.smrv.2021.101440.
PMID: 33582582 - 5
Rising pressure to understand the risks of hypertension in children with narcolepsy type 1.
Montesano E, Garcia ME, Lyon S, et al.
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2025; (21(6)):1081-1091 doi:10.5664/jcsm.11628.
PMID: 40103309 - 6
A randomized study of solriamfetol for excessive sleepiness in narcolepsy.
Thorpy MJ, Shapiro C, Mayer G, et al.
Annals of neurology 2019; (85(3)):359-370 doi:10.1002/ana.25423.
PMID: 30694576 - 7
Cardiovascular Risks in People With Narcolepsy: Expert Panel Consensus Recommendations.
Kwon Y, Gami AS, Javaheri S, et al.
Journal of the American Heart Association 2024; (13(16)):e035168 doi:10.1161/JAHA.124.035168.
PMID: 39119988 - 8
The sodium in sodium oxybate: is there cause for concern?
Avidan AY, Kushida CA
Sleep medicine 2020; (75()):497-501 doi:10.1016/j.sleep.2020.09.017.
PMID: 33022487 - 9
Calcium, magnesium, potassium, and sodium oxybates oral solution for cataplexy or excessive daytime sleepiness associated with narcolepsy.
Abad VC
Expert opinion on pharmacotherapy 2023; (24(8)):875-885 doi:10.1080/14656566.2023.2204187.
PMID: 37060579 - 10
Decreased body mass index during treatment with sodium oxybate in narcolepsy type 1.
Schinkelshoek MS, Smolders IM, Donjacour CE, et al.
Journal of sleep research 2019; (28(3)):e12684 doi:10.1111/jsr.12684.
PMID: 29504180 - 11
Weight changes during treatment with low-sodium oxybate in two phase 3 clinical studies in participants with narcolepsy or idiopathic hypersomnia.
Foldvary-Schaefer N, Skowronski R, Chandler P, et al.
Sleep medicine 2025; (133()):106602 doi:10.1016/j.sleep.2025.106602.
PMID: 40570742 - 12
Depression and suicidal thoughts in untreated and treated narcolepsy: Systematic analysis.
Barateau L, Lopez R, Chenini S, et al.
Neurology 2020; (95(20)):e2755-e2768 doi:10.1212/WNL.0000000000010737.
PMID: 32963102 - 13
ADHD in narcolepsy: A closer look at prevalence and ties.
Ren J, Zhao X, Su C, et al.
Neuroscience and biobehavioral reviews 2024; (156()):105471 doi:10.1016/j.neubiorev.2023.105471.
PMID: 38030099 - 14
The nature and magnitude of cognitive impairment in narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia: a meta-analysis.
Harel BT, Gattuso JJ, Latzman RD, et al.
Sleep advances : a journal of the Sleep Research Society 2024; (5(1)):zpae043 doi:10.1093/sleepadvances/zpae043.
PMID: 39036743 - 15
Effect of psychostimulants on blood pressure profile and endothelial function in narcolepsy.
Bosco A, Lopez R, Barateau L, et al.
Neurology 2018; (90(6)):e479-e491 doi:10.1212/WNL.0000000000004911.
PMID: 29321233 - 16
Comorbidity of obstructive sleep apnea and narcolepsy: A challenging diagnosis and complex management.
Miano S, Kheirandish-Gozal L, De Pieri M
Sleep medicine: X 2024; (8()):100126 doi:10.1016/j.sleepx.2024.100126.
PMID: 39386319 - 17
Narcolepsy and psychiatric comorbidity: a review of the literature.
Verstraete L, Van Den Bossche M
International journal of clinical and health psychology : IJCHP 2025; (25(2)):100591 doi:10.1016/j.ijchp.2025.100591.
PMID: 40546276
This page discusses long-term health monitoring for people with Narcolepsy Type 1 for informational purposes only and does not constitute medical advice. Your sleep specialist and primary care clinician should tailor screenings, medication choices, and mental health support to your needs.
Get notified when new evidence is published on narcolepsy 1.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.